Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The report of the OASIS-6 trial by Yusuf and colleagues1 showed improved survival and a tendency toward decreased severe bleeding in patients treated with the factor Xa inhibitor fondaparinux compared with unfractionated heparin (UFH) therapy. These results appear even more positive when compared with another recent trial that found increased severe bleeding with enoxaparin in ST-segment elevation myocardial infarction.2
Bhala N, Rajasekhar P, Moore I. Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction. JAMA. 2006;296(17):2087-2089. doi:10.1001/jama.296.17.2087-b